Rare EMA-Sanctioned Compassionate Use Program Sends Gilead’s Sofosbuvir To Market Early
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead Sciences sofosbuvir for hepatitis C has gained early, but restricted, entry into the EU market as the European Medicines Agency allows compassionate use at Sweden’s request.